Medifast Inc

Medifast Inc(MED)股票分析

$12.730

-0.406 (-3.19%)收盤時

Loading chart…
最高
13.220
開盤
13.080
成交量加權均價
12.81
成交量
152.10K
市值
230.99M
最低
12.470
成交金額
1.95M
企業價值/稅息折舊攤銷前利潤(TTM)
-1.79

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

AI 分析 of Medifast Inc (MED)

持有

Medifast Inc (MED) is currently trading at $12.53, showing a recent upward trend with a 5-day change of +3.47%. However, the company has reported significant losses, with a forward P/E of 12.48 indicating potential recovery but also reflecting ongoing challenges. The RSI is at 67.72, suggesting it may be nearing overbought territory. The main risk is the substantial net income loss of $17.5 million reported for Q3 2026, which raises concerns about its financial stability.

分析師評級(2)

買進
1 買進
1 持有
0 賣出
目前: 12.73
最低
—
平均
—
最高
—

Stephens

2026-02-19

目標價

$12

Equal Weight

DA Davidson

2025-02-19

目標價

$17

持有

DA Davidson

2024-11-05

目標價

$17

持有

DA Davidson

2024-07-22

目標價

$18

賣出

DA Davidson

2024-06-05

目標價

$18

賣出

估值指標

Medifast Inc(MED)目前預期本益比為 12.48,5 年平均預期本益比為 10.08。

預期本益比

合理
5 年均值 P/E
10.08
目前P/E
12.48
高估
76.00
低估
-55.84

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
1.60
目前EV/EBITDA
-1.79
高估
15.94
低估
-12.73

預期股價營收比

合理
5 年均值 P/S
0.72
目前P/S
0.54
高估
1.07
低估
0.37

Alphio AI 對 MED 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MED

$7.77

情境價格

基

基準

基準 · 50%MED

$7.58

情境價格

悲

悲觀

悲觀 · 25%MED

$5.48

情境價格

事件時間軸

2026-10-26 (ET)

08:30:00

Company Expects 2026 Revenue Between $280 Million and $300 Million

08:30:00

Sees Q4 Revenue of $55M-$75M

08:30:00

Medifast Reports Q3 Revenue of $72.05M

2026-08-27 (ET)

09:00:00

Medifast Launches Metabolic Health Institute

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

資訊

MED 常見問題 —— 由 Alphio AI 解答

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources. It operates in the Consumer Non-Cyclicals sector (MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS industry).

Medifast Inc (MED) is currently trading at $12.53, showing a recent upward trend with a 5-day change of +3.47%. However, the company has reported significant losses, with a forward P/E of 12.48 indicating potential recovery but also reflecting ongoing challenges. The RSI is at 67.72, suggesting it may be nearing overbought territory. The main risk is the substantial net income loss of $17.5 million reported for Q3 2026, which raises concerns about its financial stability.

2 analysts cover MED: 1 rate it Buy, 1 Hold and 0 Sell.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易